BACKGROUND/OBJECTIVES: Dietary supplements are popular among Korean consumers in the cross-border market. This study examined the cross-border shopping trends of dietary supplements in Korea, focusing on the major health functional foods.MATERIALS/METHODS: This study analyzed the customs clearance data provided by the Korea Customs Service, spanning 2019–2021. The term ‘health functional foods,’ which are manufactured with functional ingredients specified by law, was distinguished from the broader concept of ‘dietary supplements.’ The trends in dietary supplements and the major types of health functional foods in cross-border shopping were analyzed. The top 10 most purchased health functional foods were identified and analyzed by consumer gender and age group. RESULTS: Dietary supplements constituted 19.1% of all cross-border items, with the primary consumers being women aged 30 and 40 yrs. The most popular type of health functional foods was the ‘multi-nutrient product,’ comprising 14.5% of all health functional food items.‘Protein’ was popular among men and younger age groups, while ‘probiotics’ was favored by women. In particular, 32.3% of health functional food items were related to blood health. CONCLUSION The cross-border market for dietary supplements in Korea is experiencing growth, with consumer preferences varying by gender and age. These findings can assist in the development of regulatory policies that align with market trends and consumer needs in cross-border shopping for dietary supplements.

BACKGROUND/OBJECTIVES: Dietary supplements are popular among Korean consumers in the cross-border market. This study examined the cross-border shopping trends of dietary supplements in Korea, focusing on the major health functional foods.MATERIALS/METHODS: This study analyzed the customs clearance data provided by the Korea Customs Service, spanning 2019–2021. The term ‘health functional foods,’ which are manufactured with functional ingredients specified by law, was distinguished from the broader concept of ‘dietary supplements.’ The trends in dietary supplements and the major types of health functional foods in cross-border shopping were analyzed. The top 10 most purchased health functional foods were identified and analyzed by consumer gender and age group. RESULTS: Dietary supplements constituted 19.1% of all cross-border items, with the primary consumers being women aged 30 and 40 yrs. The most popular type of health functional foods was the ‘multi-nutrient product,’ comprising 14.5% of all health functional food items.‘Protein’ was popular among men and younger age groups, while ‘probiotics’ was favored by women. In particular, 32.3% of health functional food items were related to blood health. CONCLUSION The cross-border market for dietary supplements in Korea is experiencing growth, with consumer preferences varying by gender and age. These findings can assist in the development of regulatory policies that align with market trends and consumer needs in cross-border shopping for dietary supplements.

BACKGROUND/OBJECTIVES: Dietary supplements are popular among Korean consumers in the cross-border market. This study examined the cross-border shopping trends of dietary supplements in Korea, focusing on the major health functional foods.MATERIALS/METHODS: This study analyzed the customs clearance data provided by the Korea Customs Service, spanning 2019–2021. The term ‘health functional foods,’ which are manufactured with functional ingredients specified by law, was distinguished from the broader concept of ‘dietary supplements.’ The trends in dietary supplements and the major types of health functional foods in cross-border shopping were analyzed. The top 10 most purchased health functional foods were identified and analyzed by consumer gender and age group. RESULTS: Dietary supplements constituted 19.1% of all cross-border items, with the primary consumers being women aged 30 and 40 yrs. The most popular type of health functional foods was the ‘multi-nutrient product,’ comprising 14.5% of all health functional food items.‘Protein’ was popular among men and younger age groups, while ‘probiotics’ was favored by women. In particular, 32.3% of health functional food items were related to blood health. CONCLUSION The cross-border market for dietary supplements in Korea is experiencing growth, with consumer preferences varying by gender and age. These findings can assist in the development of regulatory policies that align with market trends and consumer needs in cross-border shopping for dietary supplements.

BACKGROUND/OBJECTIVES: Dietary supplements are popular among Korean consumers in the cross-border market. This study examined the cross-border shopping trends of dietary supplements in Korea, focusing on the major health functional foods.MATERIALS/METHODS: This study analyzed the customs clearance data provided by the Korea Customs Service, spanning 2019–2021. The term ‘health functional foods,’ which are manufactured with functional ingredients specified by law, was distinguished from the broader concept of ‘dietary supplements.’ The trends in dietary supplements and the major types of health functional foods in cross-border shopping were analyzed. The top 10 most purchased health functional foods were identified and analyzed by consumer gender and age group. RESULTS: Dietary supplements constituted 19.1% of all cross-border items, with the primary consumers being women aged 30 and 40 yrs. The most popular type of health functional foods was the ‘multi-nutrient product,’ comprising 14.5% of all health functional food items.‘Protein’ was popular among men and younger age groups, while ‘probiotics’ was favored by women. In particular, 32.3% of health functional food items were related to blood health. CONCLUSION The cross-border market for dietary supplements in Korea is experiencing growth, with consumer preferences varying by gender and age. These findings can assist in the development of regulatory policies that align with market trends and consumer needs in cross-border shopping for dietary supplements.

BACKGROUND/OBJECTIVES: Dietary supplements are popular among Korean consumers in the cross-border market. This study examined the cross-border shopping trends of dietary supplements in Korea, focusing on the major health functional foods.MATERIALS/METHODS: This study analyzed the customs clearance data provided by the Korea Customs Service, spanning 2019–2021. The term ‘health functional foods,’ which are manufactured with functional ingredients specified by law, was distinguished from the broader concept of ‘dietary supplements.’ The trends in dietary supplements and the major types of health functional foods in cross-border shopping were analyzed. The top 10 most purchased health functional foods were identified and analyzed by consumer gender and age group. RESULTS: Dietary supplements constituted 19.1% of all cross-border items, with the primary consumers being women aged 30 and 40 yrs. The most popular type of health functional foods was the ‘multi-nutrient product,’ comprising 14.5% of all health functional food items.‘Protein’ was popular among men and younger age groups, while ‘probiotics’ was favored by women. In particular, 32.3% of health functional food items were related to blood health. CONCLUSION The cross-border market for dietary supplements in Korea is experiencing growth, with consumer preferences varying by gender and age. These findings can assist in the development of regulatory policies that align with market trends and consumer needs in cross-border shopping for dietary supplements.

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of Eluvia™, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with Eluvia™ stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients.Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08–11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16– 0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of Eluvia™, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with Eluvia™ stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients.Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08–11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16– 0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of Eluvia™, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with Eluvia™ stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients.Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08–11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16– 0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of Eluvia™, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with Eluvia™ stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients.Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08–11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16– 0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

Background: The benefits of transradial access (TRA) over transfemoral access (TFA) for bifurcation percutaneous coronary intervention (PCI) are uncertain because of the limited availability of device selection. This study aimed to compare the procedural differences and the in-hospital and long-term outcomes of TRA and TFA for bifurcation PCI using secondgeneration drug-eluting stents (DESs). Methods: Based on data from the Coronary Bifurcation Stenting Registry III, a retrospective registry of 2,648 patients undergoing bifurcation PCI with second-generation DES from 21 centers in South Korea, patients were categorized into the TRA group (n = 1,507) or the TFA group (n = 1,141). After propensity score matching (PSM), procedural differences, in-hospital outcomes, and device-oriented composite outcomes (DOCOs; a composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) were compared between the two groups (772 matched patients each group). Results: Despite well-balanced baseline clinical and lesion characteristics after PSM, the use of the two-stent strategy (14.2% vs. 23.7%, P = 0.001) and the incidence of in-hospital adverse outcomes, primarily driven by access site complications (2.2% vs. 4.4%, P = 0.015), were significantly lower in the TRA group than in the TFA group. At the 5-year follow-up, the incidence of DOCOs was similar between the groups (6.3% vs. 7.1%, P = 0.639). Conclusion The findings suggested that TRA may be safer than TFA for bifurcation PCI using second-generation DESs. Despite differences in treatment strategy, TRA was associated with similar long-term clinical outcomes as those of TFA. Therefore, TRA might be the preferred access for bifurcation PCI using second-generation DES.